Medicine
Exjade 250 mg tablet for oral suspension
Exjade 250 mg tablet for oral suspension is a prescription medicine containing Deferasirox for oral use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store Exjade tablets at 20°C to 25°C (68°F to 77°F), excursions are permitted…
Key facts
- Active ingredient (INN)
- Deferasirox
- Brand
- Exjade
- Strength
- 250 mg
- Dosage form
- Tablet for oral suspension
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store Exjade tablets at 20°C to 25°C (68°F to 77°F), excursions are permitted between 15°C to 30°C (59°F to 86°F). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AC03 Deferasirox
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 November 2005
- Identifiers
- RxCUI 597768, 597770, 597772 +3DailyMed set ID 3495a70c-870c-4968-940e-8baea152cf85NDC 0078-0469Application NDA021882
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, for suspension in 1 bottle | 0078-0469-15 | Novartis Pharmaceuticals | 30 November 2005 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Deferasirox 250 mg tablet for oral suspension.
Other strengths and forms of Deferasirox
Clinical summary
Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, among other approved uses. MedsAcross supplies Deferasirox for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DeferasiroxFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Exjade prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Exjade: European public assessment report (EPAR) · European Medicines Agency
- Deferasirox Accord: European public assessment report (EPAR) · European Medicines Agency
Need Exjade 250 mg tablet for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.